Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs

Livia Dézsi, L. Vécsei

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Parkinson's disease is a neurodegenerative disorder characterized by the loss of striatal dopaminergic neurons. Besides the improvement of the dopaminergic loss, the treatment focuses on non-dopaminergic medication targeting motor and non-motor symptoms, and on the development of neuroprotective medication. A good knowledge of the properties of the compounds used is essential not only for those involved in pharmacological research but also for those who treat Parkinson's disease patients, facing their still many unmet needs. Areas covered: The review discusses the pharmacokinetic properties of levodopa (LD) and factors influencing them, the pharmacodynamics of LD and approaches with the aim of improving this, covering some of the other antiparkinson medications available. Among the non-dopaminergic agents, it focuses on research on kynurenines. A literature search was made in PubMed for Parkinson's disease treatment, LD, LD absorption, LD pharmacokinetics, continuous dopaminergic stimulation, LD-carbidopa intraintestinal gel therapy, dopamine agonists and monoamine oxidase-B inhibitors. Expert opinion: Various factors can cause irregularities in the pharmacokinetics of LD, with interconnected consequences on its therapeutic effect. Its long-term use is associated with the development of motor complications; this is explained mostly by pharmacodynamic and also by pharmacokinetic properties, the latter gaining importance in the advanced stages of the disease.

Original languageEnglish
Pages (from-to)409-424
Number of pages16
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume10
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Antiparkinson Agents
Levodopa
Pharmacokinetics
Pharmacodynamics
Parkinson Disease
Kynurenine
Corpus Striatum
Monoamine Oxidase Inhibitors
Dopaminergic Neurons
Dopamine Agonists
Monoamine Oxidase
Expert Testimony
Therapeutic Uses
Research
PubMed
Neurodegenerative Diseases
Neurons
Therapeutics
Gels
Pharmacology

Keywords

  • Continuous dopaminergic stimulation
  • Dopamine agonists
  • Kynurenines
  • Levodopa
  • Levodopa pharmacokinetics
  • Levodopa-carbidopa intraintestinal gel therapy
  • Monoamine oxidase-B inhibitors
  • Parkinson's disease

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Medicine(all)

Cite this

Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs. / Dézsi, Livia; Vécsei, L.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, No. 3, 03.2014, p. 409-424.

Research output: Contribution to journalArticle

@article{9391ba2bf3a547d48b5c214d1c016c42,
title = "Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs",
abstract = "Introduction: Parkinson's disease is a neurodegenerative disorder characterized by the loss of striatal dopaminergic neurons. Besides the improvement of the dopaminergic loss, the treatment focuses on non-dopaminergic medication targeting motor and non-motor symptoms, and on the development of neuroprotective medication. A good knowledge of the properties of the compounds used is essential not only for those involved in pharmacological research but also for those who treat Parkinson's disease patients, facing their still many unmet needs. Areas covered: The review discusses the pharmacokinetic properties of levodopa (LD) and factors influencing them, the pharmacodynamics of LD and approaches with the aim of improving this, covering some of the other antiparkinson medications available. Among the non-dopaminergic agents, it focuses on research on kynurenines. A literature search was made in PubMed for Parkinson's disease treatment, LD, LD absorption, LD pharmacokinetics, continuous dopaminergic stimulation, LD-carbidopa intraintestinal gel therapy, dopamine agonists and monoamine oxidase-B inhibitors. Expert opinion: Various factors can cause irregularities in the pharmacokinetics of LD, with interconnected consequences on its therapeutic effect. Its long-term use is associated with the development of motor complications; this is explained mostly by pharmacodynamic and also by pharmacokinetic properties, the latter gaining importance in the advanced stages of the disease.",
keywords = "Continuous dopaminergic stimulation, Dopamine agonists, Kynurenines, Levodopa, Levodopa pharmacokinetics, Levodopa-carbidopa intraintestinal gel therapy, Monoamine oxidase-B inhibitors, Parkinson's disease",
author = "Livia D{\'e}zsi and L. V{\'e}csei",
year = "2014",
month = "3",
doi = "10.1517/17425255.2014.878702",
language = "English",
volume = "10",
pages = "409--424",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs

AU - Dézsi, Livia

AU - Vécsei, L.

PY - 2014/3

Y1 - 2014/3

N2 - Introduction: Parkinson's disease is a neurodegenerative disorder characterized by the loss of striatal dopaminergic neurons. Besides the improvement of the dopaminergic loss, the treatment focuses on non-dopaminergic medication targeting motor and non-motor symptoms, and on the development of neuroprotective medication. A good knowledge of the properties of the compounds used is essential not only for those involved in pharmacological research but also for those who treat Parkinson's disease patients, facing their still many unmet needs. Areas covered: The review discusses the pharmacokinetic properties of levodopa (LD) and factors influencing them, the pharmacodynamics of LD and approaches with the aim of improving this, covering some of the other antiparkinson medications available. Among the non-dopaminergic agents, it focuses on research on kynurenines. A literature search was made in PubMed for Parkinson's disease treatment, LD, LD absorption, LD pharmacokinetics, continuous dopaminergic stimulation, LD-carbidopa intraintestinal gel therapy, dopamine agonists and monoamine oxidase-B inhibitors. Expert opinion: Various factors can cause irregularities in the pharmacokinetics of LD, with interconnected consequences on its therapeutic effect. Its long-term use is associated with the development of motor complications; this is explained mostly by pharmacodynamic and also by pharmacokinetic properties, the latter gaining importance in the advanced stages of the disease.

AB - Introduction: Parkinson's disease is a neurodegenerative disorder characterized by the loss of striatal dopaminergic neurons. Besides the improvement of the dopaminergic loss, the treatment focuses on non-dopaminergic medication targeting motor and non-motor symptoms, and on the development of neuroprotective medication. A good knowledge of the properties of the compounds used is essential not only for those involved in pharmacological research but also for those who treat Parkinson's disease patients, facing their still many unmet needs. Areas covered: The review discusses the pharmacokinetic properties of levodopa (LD) and factors influencing them, the pharmacodynamics of LD and approaches with the aim of improving this, covering some of the other antiparkinson medications available. Among the non-dopaminergic agents, it focuses on research on kynurenines. A literature search was made in PubMed for Parkinson's disease treatment, LD, LD absorption, LD pharmacokinetics, continuous dopaminergic stimulation, LD-carbidopa intraintestinal gel therapy, dopamine agonists and monoamine oxidase-B inhibitors. Expert opinion: Various factors can cause irregularities in the pharmacokinetics of LD, with interconnected consequences on its therapeutic effect. Its long-term use is associated with the development of motor complications; this is explained mostly by pharmacodynamic and also by pharmacokinetic properties, the latter gaining importance in the advanced stages of the disease.

KW - Continuous dopaminergic stimulation

KW - Dopamine agonists

KW - Kynurenines

KW - Levodopa

KW - Levodopa pharmacokinetics

KW - Levodopa-carbidopa intraintestinal gel therapy

KW - Monoamine oxidase-B inhibitors

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84894195926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894195926&partnerID=8YFLogxK

U2 - 10.1517/17425255.2014.878702

DO - 10.1517/17425255.2014.878702

M3 - Article

C2 - 24437461

AN - SCOPUS:84894195926

VL - 10

SP - 409

EP - 424

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 3

ER -